A phase II, open-label, randomized trial of durvalumab (D) with olaparib (O) or cediranib (C) in patients (pts) with leiomyosarcoma (LMS).
Olubukola Ayodele,Ben X. Wang, Thomas D. Pfister,Esmail Mutahar Al-Ezzi,Hal Berman,Aaron Richard Hansen,Abha A. Gupta,Anna Spreafico, Limore Arones,Philippe L. Bedard,Lindsay Carlsson,Marcus O. Butler,Benjamin Haibe-Kains,Wei Xu,Lillian L. Siu,Albiruni Ryan Abdul Razak JOURNAL OF CLINICAL ONCOLOGY（2021）
AI 理解论文
溯源树
样例
